Astellas gets rights to Chromocell's pain candidates; Deal Terminated
Executive Summary
In its first pharma partnership, Chromocell Corp. licensed Astellas Pharma Inc. worldwide rights to develop and commercialize CC8464 and back-up candidates to treat neuropathic and other types of pain.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Technologies
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice